Get started
Author

Julia Hieulle

Observed name: Julia HIEULLE
ORCID: 0009-0005-0947-2789
Observed ORCID: 0009-0005-0947-2789
OpenAlex ID: A5079123080
Treatment with temozolomide and ibrutinib in recurrent/refractory primary (PCNSL) and secondary CNS lymphoma (SCNSL)
2021 · Loïc Renaud, Jean Baptiste Bossard, et al. · European Journal Of Haematology · 35
Treatment with Temozolomide and Ibrutinib in Recurrent/Refractory Primary (PCNSL) and Secondary CNS Lymphoma (SCNSL)
2020 · Loïc Renaud, Jean-Baptiste Bossard, et al. · Blood · 8
Myélome multiple : des critères diagnostiques et pronostiques renouvelés et de forts espoirs thérapeutiques
2019 · Salomon Manier, Marie de Charette de la Contrie, et al. · La Presse Médicale · 5
PDF
Efficacy and Safety of Daratumumab in a Frail Real-Life Relapsed or Refractory Systemic Light-Chain Amyloidosis Population (AL): Report on 15 Cases from the North of France
2018 · Zoe Van De Wyngaert, Benjamin Carpentier, et al. · Blood · 5
Diagnostic relevance of SH2B3 mutations in suspected myeloid malignancies and acute leukemia: insights from a large-scale NGS-based screening study
2025 · Leïla Ben Dhia, Mathieu Wemeau, et al. · Blood Cancer Journal · 3
PDF
Targeted therapies overcome the poor prognosis of stereotyped Subset#2 chronic lymphocytic leukemia : a real-world multicentric study
2025 · Lucile Bussot, Stéphanie Poulain, et al. · Leukemia · 2
PDF
Treatment Bridging With a 28-Day Metronomic Therapy (Metro-28) for Relapsed Refractory Multiple Myeloma
2021 · Tarek H. Mouhieddine, Julia Hieulle, et al. · Clinical Lymphoma Myeloma & Leukemia · 2
Real life study of ivosidenib in either monotherapy or combined with azacytidine for first line mutant IDH1 AML: A study from the french AML intergroup ALFA/filo
2025 · Pierre Peterlin, Mael Heiblig, et al. · Blood · 1
PDF
Diagnostic relevance of SH2B3 mutations in suspected myeloid malignancies: Insights from a large-scale NGS-based screening study
2025 · Leïla BEN DHIA, Mathieu Wemeau, et al. · Blood · 1
PDF
Real-life CD34+CD38- leukemic stem cell (LSC) flow quantification in adult AML at diagnosis independently predicts survival of intensively but not AZA-VEN treated patients: A study of prospective observational ALFA-PPP acute leukemia french association
2025 · Adriana Plesa, Alexandra COELHO, et al. · Blood · 1
Ivosidenib in refractory or relapsed IDH1-mutated Acute Myeloid Leukemia patients in real life settings: The ivoobs observational study from the french AML intergroup ALFA/filo
2025 · Mael Heiblig, Pierre Peterlin, et al. · Blood · 1
PDF
Comprehensive mutational profiling and clinical outcome of adult acute myeloid leukemia patients with NUP98 rearrangement
2026 · Benoit Ducourneau, Arnaud Pages, et al. · Leukemia
Real life treatments and outcomes of older patients aged more than 60 years with FLT3-mutated acute myeloid leukemia: Report from the multicentric french observational ALFA-PPP study
2025 · Ramy Rahmé, Emmanuel Raffoux, et al. · Blood
PDF
28-Day Metronomic Therapy for Relapsed Refractory Multiple Myeloma
2020 · Tarek H Mouhieddine, Julia Hieulle, et al. · Blood
Works count: 14
Citation count: 64
H-index: 4
I10-index: 1
Year
Topic
Type